IMM-H007

IMM-H007 is a potent TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK (AMP-activated protein kinase). IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].

Signaling Pathways >> Epigenetics >> AMPK

Research Areas >> Cardiovascular Disease

Research Areas >> Inflammation/Immunology

Signaling Pathways >> PI3K/Akt/mTOR >> AMPK

Research Areas >> Metabolic Disease

Signaling Pathways >> MAPK/ERK Pathway >> JNK

IMM-H007 inhibits fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulates fatty acid oxidation, autophagy, and export of hepatic lipids[2].

[1]. Yu J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732.

[2]. Shi H, et al. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7(9):1379-1391.

[3]. Wang SX, et al. IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway. Acta Pharmacol Sin. 2022 Mar 30.